BERLIN -- A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line ...
Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.
First-in-human study of RAG-01: A novel small activating RNA therapeutic in BCG failure non-muscle invasive bladder cancer (NMIBC) patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
At 16, I knew something was wrong. Little did I know my rare condition would take several specialists and seven years to diagnose.
Continued approval of this tumor agnostic indication is contingent upon verification of clinical benefit in a confirmatory trial. The Food and Drug Administration (FDA) has granted accelerated ...
Medical professionals use CT scans to help diagnose and stage bladder cancer. While CT scans can provide valuable information, they are not perfect and have certain limitations. However, CT scans may ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results